Épimède
Venture capitalLiège · Seed–Series B · 1 people tracked
Investment thesis
Épimède invests in private, non-listed early-stage technology SMEs with demonstrated or effective growth potential, prioritizing companies whose registered or principal operating office is located in Wallonia. Investments primarily fund capital increases to support growth leaps, with secondary secondary purchases of existing shares. The fund targets companies with fewer than 500 employees, net fixed assets under €75M, and independence from large corporates. Preferred sectors include life sciences (biology, biotech, medtech), engineering sciences (ICT and cleantech), and business services, always requiring a technological or industrial competitive advantage. Épimède takes an active board role and offers hands-on strategic support and network access.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from public directories
Frequently asked questions
- What stage does Épimède invest at?
- Épimède invests at the Seed, Series A, Series B stages.
- What is Épimède's typical check size?
- Épimède typically writes checks of $1.1M – $7.6M.
- What sectors does Épimède focus on?
- Épimède focuses on Biotech, Cleantech, Deep Tech, Enterprise Software, Medical Devices, New Materials.
- Where is Épimède located?
- Épimède is headquartered in Liège, BE.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
UTEC is a venture capital firm that invests in seed and early-stage technology companies and is affiliated with the University of Tokyo.